Loading…
AAALAC-accreditedUSDA-licensedPreclinical research & animal resources for global programs +1 (843) 589-5190 info@alphagenesisinc.com
Research animal retirement and lifetime care, now available through Alpha Genesis. Professionally managed lifetime care for retired research primates, with expert social reintroduction into stable outdoor groups led by veterinary staff deeply experienced in laboratory-animal medicine.
Learn moreCapabilities
Study capabilities spanning pharmacology and PK/PD, toxicology and safety, reproductive toxicology (DART), infectious disease and vaccines, immunology, oncology, neuroscience, gene therapy, surgical models, and biospecimen collection, delivered as GLP and non-GLP study support.
Capabilities are delivered across rodent and NHP models, allowing sponsors to match the model to the scientific question and advance programs with continuity from early in vivo work into translational studies.
Each capability is supported by veterinary leadership, trained technical teams, SOP-driven operations, and documentation designed for sponsor audit readiness.
From exploratory non-GLP pilot work through GLP-aligned documentation for IND-enabling studies, Alpha Genesis supports every regulatory stage, at the depth North American and international programs expect, with quality systems, data integrity, and audit readiness at the core.
Learn moreRigorous in-life pharmacology and pharmacokinetic/pharmacodynamic studies in rodent and NHP models, designed to characterize efficacy, define dose-response relationships, and generate translatable exposure data for development programs advancing on North American and international timelines.
Learn moreSingle-dose and repeat-dose toxicity, tolerability, and safety pharmacology studies in rodent and NHP models, executed with GLP-aligned documentation, veterinary clinical oversight, and the audit and inspection readiness that global regulatory submissions demand.
Learn moreFertility, embryo-fetal, and pre- and postnatal development studies in rat and NHP models.
Learn moreVaccine immunogenicity, efficacy, and immune-response characterization in NHP and rodent models, supporting infectious disease and biodefense research under appropriate biosafety controls and with full veterinary and regulatory documentation.
Learn moreTranslational immunology studies in NHP and rodent models, including immunophenotyping, PBMC isolation, cytokine and biomarker analysis coordination, and longitudinal immune monitoring to characterize drug and vaccine effects on the immune system.
Learn moreEfficacy, pharmacokinetic/pharmacodynamic, tolerability, and biodistribution studies in rodent tumor models and NHP translational programs, designed to generate interpretable oncology data under welfare-centered, rigorous in-life conditions.
Learn moreCNS-focused studies in NHP and rodent models, with behavioral monitoring, surgical and interventional approaches, and coordinated biospecimen collection including CSF, supporting neuroscience drug development with welfare-centered rigor.
Learn moreIn-life support for AAV and other gene-therapy programs across rodent and NHP models, from early proof-of-concept in disease models through translational biodistribution, immunogenicity, and GLP-aligned safety studies, with the dosing routes, sampling, and veterinary oversight these vectors demand.
Learn moreCustom surgical and interventional model development, catheterization, cannulation, and perioperative veterinary care in NHP and rodent models, delivering study designs that require precision, animal welfare expertise, and disciplined post-operative management.
Learn moreSerial and terminal biospecimen collection in NHP and rodent models, blood, serum, plasma, PBMCs, CSF, urine, and tissue, with custom protocol design, in-house processing, cryopreservation, and coordinated shipment to sponsor or partner laboratories.
Learn moreClinical pathology, in-house sample processing, bioanalysis coordination, structured data capture, and biospecimen logistics that connect in-life study execution to the analytical and reporting outputs your program requires.
Learn moreShare your objectives, species, study type, and timeline. A member of our scientific or business-development team will review your request and follow up to discuss feasibility, timing, and next steps.